WASHINGTON

2020

WASHINGTON

MAY 4, 2020

WELCOME

THE E-CIGARETTE SUMMIT USA 2020

COVID 19 – Important Update
It is with regret that we have had to take the decision to cancel the forthcoming E-Cigarette Summit on May 4, 2020. We are tentatively holding a postponed date for 31 August 2020, if it becomes clear that the situation has dramatically improved.

We will be refunding 100% of ticket sales and hotel rooms for the May date and all bookings for August will be made on a refundable basis.  If you have any questions please email info@smooth-events.com. We look forward to meeting you all again under happier and healthier times.

 

The Summit will be Chaired by Professor Thomas Glynn, Stanford University School of Medicine and the opening address will be delivered by Steven A. Schroeder MD, Distinguished Professor of Health and Healthcare at the University of California San Francisco (UCSF), where he also directs the Smoking Cessation Leadership Center.
Since the inaugural US Summit in 2017 which welcomed over 300 attendees, the tobacco control and policy landscape has continued to change. This year’s E-Cigarette Summit USA comes at a major US policy and regulatory crossroads and looks to provide an evidence based environment that encourages open and respectful dialogue on the key science and current public health topics, with a single aim of reducing smoking related death and disease.
The role that e-cigarettes could play in ending or extending the smoking epidemic is likely to remain one of the most fiercely fought debates in public health history. We cannot answer every question yet, but we believe that progress is not only possible but imperative. These first important steps to regulate an entirely novel product category will set the agenda for decades to come and is likely to be viewed as a pivotal era in both tobacco control and combustible tobacco use in the future.

…Read More

SUMMIT CHAIR 2020

Prof Thomas Glynn

Stanford University School of Medicine

Prof Thomas J. Glynn, Stanford University School of Medicine

CONFIRMED SUMMIT SPEAKERS 2020

Deborah Arnott

Chief Executive

Action on Smoking and Health (UK)

Prof Dorothy Hatsukami

Professor, Department of Psychiatry

Associate Director of Cancer Prevention and Control for the Masonic Cancer Center, University of Minnesota

Prof Jasjit S. Ahluwalia

Professor, Behavioural and Social Sciences & Internal Medicine

Brown University, School of Public Health & Alpert School of Medicine

Clive Bates

Director

Counterfactual Consulting Ltd

Dr. Nancy A. Rigotti, MD

Professor of Medicine, Harvard Medical School

Director, Tobacco Research & Treatment Center, Massachusetts General Hospital, Boston

Kathleen Crosby

Director, Office of Health Communication & Education

FDA Center for Tobacco Products

Prof Richard Miech

Principal Investigator, Monitoring the Future

Institute for Social Research, Universithy of Michigan

Jim Solyst

Consultant to Swedish Match

JMS Scientific Engagement

Prof David Levy

Professor of Oncology

Lombardl Comprehensive Cancer Center, Georgetown University

Dr Mike Cummings

Professor, Dep't Psychiatry & Behavioural Sciences

Medical University of South Carolina

Pamela Kaufman

Morgan Stanley

David Graham

Chief Impact Officer

NJOY

Andy Hyland

Scientific Principal Investigator

PATH Study Roswell Park Comprehensive Cancer Center

Prof Peter Hajek

Professor of Clinical Psychology

Queen Mary University of London

Stephanie Miller

Co-Founder

Sandhill Strategy

Prof Kenneth Warner

Professor Emeritus and Dean Emeritus

School of Public Health, University of Michigan

Dr Ray Niaura

Director for Science

Schroeder Institute at Truth Initiative

Prof Thomas J. Glynn, PhD

Adjunct Lecturer

Stanford Prevention Research Centre, Stanford University School of Medicine

Dr Amy L. Fairchild

Dean College of Public Health

The Ohio State University

Matthew R. Holman

Director, Office of Science (OS),Center for Tobacco Products (CTP)

U.S. Food and Drug Administration

Professor Ann McNeill

Professor of Tobacco Addiction

UK Centre for Tobacco and Alcohol Studies (UKCTAS), Kings College London

Prof Steven A. Schroeder MD

Distinguished Professor of Health and Healthcare

University of California, San Francisco & Director, Smoking Cessation Leadership Center

Prof Neal L. Benowitz

Professor of Medicine and Bioengineering & Theapeutic Sciences

University of California, San Franciso

Ass’t Prof Jennifer Pearson

Assistant Professor

University of Nevado, Reno

Prof Andrea Villanti

Associate Professor of Psychiatry and Psychology

Vermont Center on Behavior & Health, at the University of Vermont

WHAT QUESTIONS WILL BE EXPLORED?

The E-Cigarette Summit provides an evidence based environment that encourages open and respectful dialogue on the key science and current public health topics. The format includes high level briefings from global experts followed by panel discussions and audience Q&A.

  • What are the key considerations for prudent regulation of e-cigarettes?
  • How do we maximize benefits for smokers and minimize potential harms for youth?
  • Understanding youth use – how should data be interpreted and presented?
  • How do we educate youth without confusing adult smokers
  • How should the evidence on e-cigarettes and the harm continuum be communicated to the American public – how can we better help the public understand relative risks?
  • Is the current and proposed regulatory regime for e-cigarettes fit for purpose or does it need to be reformed and, if so, what needs to be considered to achieve maximum benefits for public health?
  • Are American youth experimenting with e-cigarettes more than other countries – what are the appropriate measures?
  • Is dual use an important step in cessation or a failing of harm reduction?
  • What direction should the FDA take with e-cigarettes and tobacco control – what are the main priorities for current smokers?  And for preventing youth initiation?  Are these two priorities compatible?
  • Current and future research priorities
  • Why has tobacco harm reduction proved to be such a divisive issue – how can we improve dialogue and collaboration?

WHO SHOULD ATTEND

The E-Cigarette Summit is particularly relevant to:

  • Regulators and policy advisors
  • Health providers and public health advocates
  • National, state and local legislators and their staffs
  • Public health professionals
  • Scientific/research community
  • Medical and health professionals
  • e-cigarette industry stakeholders

WHO SHOULD ATTEND

  • Regulators and policy advisors
  • Health providers and public health advocates
  • National, state and local legislators and their staffs
  • Public health professionals
  • Scientific/research community
  • Medical and health professionals
  • e-cigarette industry stakeholders